

CERUS CORP  
Form 8-K  
November 22, 2006

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): November 21, 2006

**CERUS CORPORATION**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State of jurisdiction)

**0-21937**  
(Commission

**68-0262011**  
(IRS Employer

File No.)  
**2411 Stanwell Drive**

Identification No.)

**Concord, California 94520**

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: (925) 288-6000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ..  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ..  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ..  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Edgar Filing: CERUS CORP - Form 8-K

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 8.01. Other Events.**

On November 21, 2006, Cerus Corporation (the Company) announced that it has received a European CE mark certificate for its INTERCEPT Blood System for plasma. A copy of the Company's press release, entitled Cerus Corporation Announces European Regulatory Approval for the INTERCEPT Blood System for Plasma, is attached hereto as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

- 99.1 Press Release, dated November 21, 2006, entitled Cerus Corporation Announces European Regulatory Approval for the INTERCEPT Blood System for Plasma.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CERUS CORPORATION**

Dated: November 21, 2006

By: /s/ William J. Dawson  
William J. Dawson

Vice President, Finance and Chief Financial Officer

**EXHIBIT INDEX**

<b>Number</b>	<b>Description</b>
99.1	Press Release, dated November 21, 2006, entitled Cerus Corporation Announces European Regulatory Approval for the INTERCEPT Blood System for Plasma.